Gsk 3Β is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Glycogen synthase kinase-3 beta (GSK-3β) is a constitutively active serine/threonine protein kinase encoded by the [GSK3B[/proteins/[gsk3b[/proteins/[gsk3b[/proteins/[gsk3b[/proteins/[gsk3b--TEMP--/proteins)--FIX--(gsk3b) gene on chromosome 3q13.33. [Originally identified for its role in glycogen metabolism, GSK-3β is now recognized as one of the most versatile kinases in the central nervous system, with over 100 known substrates spanning metabolism, gene expression, cell cycle regulation, and [neurons[/cell-types/[neurons[/cell-types/[neurons[/cell-types/[neurons[/cell-types/[neurons--TEMP--/cell-types)--FIX--(/cell-types/neurons) function. In neurodegenerative disease research, GSK-3β has emerged as a central player in [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX-- pathogenesis due to its role as the primary kinase responsible for tau] hyperphosphorylation at pathologically relevant epitopes https://pubmed.ncbi.nlm.nih.gov/15890656/).
GSK-3β phosphorylates tau] at more than 30 disease-associated sites, directly promoting the formation of neurofibrillary tangles. It also
serves as a molecular link between [amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- toxicity and tau] pathology—[Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- oligomers activate GSK-3β, which in turn drives tau]
hyperphosphorylation, creating a feed-forward cycle that accelerates neurodegeneration [2]. The enzyme has consequently been one of the most intensively
pursued therapeutic targets in [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--, with multiple inhibitors tested in [clinical trials[/[clinical-trials[/[clinical-trials[/[clinical-trials[/[clinical-trials[/[clinical-trials[/[clinical-trials[/[clinical-trials[/clinical-trials [3].
¶ Structure and Regulation
GSK-3β is a 46 kDa monomeric kinase belonging to the CMGC family of serine/threonine kinases. It exists as two isoforms encoded by separate genes: GSK-3α (51 kDa, chromosome 19) and GSK-3β (46 kDa, chromosome 3). GSK-3β contains:
- N-terminal domain: Contains the inhibitory Ser9 phosphorylation site and a β-strand-rich region
- Kinase domain: Bilobal structure with ATP-binding site in the cleft between N- and C-terminal lobes
- Activation loop: Contains the activating Tyr216 autophosphorylation site
- C-terminal tail: Involved in substrate recognition and protein-protein interactions
A critical and unusual feature of GSK-3β is its constitutive activity—unlike most kinases that require activation, GSK-3β is active in
resting cells and is regulated primarily through inhibitory mechanisms [4].
- Tyr216 (GSK-3β) / Tyr279 (GSK-3α): Autophosphorylation of this activation loop residue enhances catalytic activity. This phosphorylation occurs co-translationally and is constitutive
- Ser9 (GSK-3β) / Ser21 (GSK-3α): Inhibitory phosphorylation by Akt/PKB, p70S6K, PKA, PKC, and p90RSK. The phosphorylated N-terminus acts as a pseudo-substrate, occupying the primed-substrate binding site and blocking kinase activity [5]
GSK-3β exhibits a strong preference for substrates pre-phosphorylated ("primed") at a serine or threonine located 4 residues C-terminal to
the target site (S/T-X-X-X-pS/pT motif). This priming requirement means GSK-3β often acts as a secondary kinase after an initial "priming
kinase" (e.g., [CDK5[/entities/[cdk5[/entities/[cdk5[/entities/[cdk5[/entities/[cdk5--TEMP--/entities)--FIX--, CK1, DYRK1A) phosphorylates the substrate. However, some substrates—including certain tau] epitopes—can be
phosphorylated without priming [2].
- Wnt signaling: In the canonical Wnt pathway, GSK-3β is sequestered in a destruction complex with APC, Axin, and CK1. Wnt ligand binding to Frizzled receptors inhibits GSK-3β, stabilizing β-catenin
- Protein complexes: Scaffolding proteins (Axin, FRAT/GBP) regulate GSK-3β substrate specificity and subcellular localization
- Subcellular localization: Found in cytoplasm, nucleus, and mitochondria, with compartment-specific functions
¶ Neuronal Development and Polarity
GSK-3β is essential for neuronal differentiation, axon specification, and axon elongation. It phosphorylates collapsin response mediator
protein 2 (CRMP-2) and adenomatous polyposis coli (APC) to regulate microtubule dynamics and axonal growth cone behavior. GSK-3β activity
must be tightly regulated during neurodevelopment—both excessive and insufficient activity impair neuronal morphogenesis [6].
GSK-3β regulates [long-term potentiation[/entities/[long-term-potentiation[/entities/[long-term-potentiation[/entities/[long-term-potentiation[/entities/[long-term-potentiation--TEMP--/entities)--FIX-- ([LTP[/entities/[long-term-potentiation[/entities/[long-term-potentiation[/entities/[long-term-potentiation[/entities/[long-term-potentiation--TEMP--/entities)--FIX-- and long-term depression (LTD) at hippocampal synapses. Active GSK-3β facilitates LTD and
inhibits [LTP[/entities/[long-term-potentiation[/entities/[long-term-potentiation[/entities/[long-term-potentiation[/entities/[long-term-potentiation--TEMP--/entities)--FIX--, while Ser9 phosphorylation (GSK-3β inhibition) promotes [LTP[/entities/[long-term-potentiation[/entities/[long-term-potentiation[/entities/[long-term-potentiation[/entities/[long-term-potentiation--TEMP--/entities)--FIX--. This bidirectional regulation positions GSK-3β as a molecular
switch controlling the direction of synaptic plasticity and memory formation [7].
- Glycogen synthesis: GSK-3β phosphorylates and inhibits glycogen synthase, reducing glycogen storage—its originally described function
- Insulin signaling: PI3K/Akt pathway activation leads to GSK-3β Ser9 phosphorylation, linking insulin signaling to metabolic regulation. Brain insulin resistance impairs this pathway in AD
- Transcription factor regulation: GSK-3β modulates β-catenin (Wnt pathway), CREB, [NF-κB[/entities/[nf-kb[/entities/[nf-kb[/entities/[nf-kb[/entities/[nf-kb--TEMP--/entities)--FIX--, Snail, c-Myc, NFAT, and numerous other transcription factors
- [autophagy[/entities/[autophagy[/entities/[autophagy[/entities/[autophagy[/entities/[autophagy--TEMP--/entities)--FIX--: Modulates autophagy through [TFEB[/entities/[tfeb[/entities/[tfeb[/entities/[tfeb[/entities/[tfeb--TEMP--/entities)--FIX-- phosphorylation and [mTOR[/mechanisms/[mtor-neurodegeneration[/mechanisms/[mtor-neurodegeneration[/mechanisms/[mtor-neurodegeneration[/mechanisms/[mtor-neurodegeneration--TEMP--/mechanisms)--FIX-- signaling
GSK-3β is the principal kinase driving pathological tau]/Biomarker/diagnosticsplasma-biomarkers) (CSF [p-tau181) |
| Ser202/Thr205 | AT8 | Early tau pathology], [Braak staging[/mechanisms/[braak-staging[/mechanisms/[braak-staging[/mechanisms/[braak-staging[/mechanisms/[braak-staging--TEMP--/mechanisms)--FIX-- |
| Thr231 | AT180 | Microtubule binding impairment |
| Ser262 | 12E8 | Microtubule detachment (with MARK/PAR-1) |
| Ser396/Ser404 | PHF-1 | [Late[/diseases/[late[/diseases/[late[/diseases/[late[/diseases/[late--TEMP--/diseases)--FIX-- tangle epitope |
| Ser422 | — | Promotes tau] aggregation |
A landmark 2024 study in PNAS demonstrated that GSK-3β phosphorylation of full-length tau] is sufficient to catalyze aggregation into
AD-type paired helical filaments (PHFs), directly linking kinase hyperactivity to tangle formation [8]. In tau]-expressing mouse models, GSK-3β overexpression drives hippocampal degeneration and
learning deficits, while GSK-3β deletion attenuates these phenotypes [9].
¶ Link Between Amyloid and Tau Pathology
GSK-3β is a critical mediator connecting [amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- accumulation to tau] pathology:
- [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- activates GSK-3β: Soluble [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- oligomers impair PI3K/Akt signaling, reducing inhibitory Ser9 phosphorylation and increasing GSK-3β activity
- GSK-3β increases [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- production: GSK-3β phosphorylates [presenilin-1[/proteins/[presenilin-1[/proteins/[presenilin-1[/proteins/[presenilin-1[/proteins/[presenilin-1--TEMP--/proteins)--FIX--, enhancing γ-secretase activity and shifting [APP[/genes/[app[/genes/[app[/genes/[app[/genes/[app--TEMP--/genes)--FIX--
- GSK-3β inhibition is neuroprotective in MPTP and 6-OHDA models of PD [12]
- GSK-3β activity is elevated in [spinal cord[/brain-regions/[spinal-cord[/brain-regions/[spinal-cord[/brain-regions/[spinal-cord[/brain-regions/[spinal-cord--TEMP--/brain-regions)--FIX-- motor [neurons[/cell-types/[neurons[/cell-types/[neurons[/cell-types/[neurons[/cell-types/[neurons--TEMP--/cell-types)--FIX-- in [ALS[/diseases/[als[/diseases/[als[/diseases/[als[/diseases/[als--TEMP--/diseases)--FIX--
- Phosphorylates [TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43--TEMP--/entities)--FIX--, promoting its cytoplasmic mislocalization and aggregation
- Tideglusib (a non-ATP competitive GSK-3β inhibitor) has been explored as an ALS therapeutic
- GSK-3β contributes to [mutant [huntingtin[/proteins/[huntingtin[/proteins/[huntingtin[/proteins/[huntingtin[/proteins/[huntingtin--TEMP--/proteins)--FIX-- toxicity and striatal neurodegeneration
- Phosphorylation of [huntingtin[/proteins/[huntingtin[/proteins/[huntingtin[/proteins/[huntingtin[/proteins/[huntingtin--TEMP--/proteins)--FIX--(/proteins/huntingtin) by GSK-3β modulates its aggregation and toxicity
- GSK-3β inhibition shows protective effects in HD models
| Compound |
Type |
Status |
Indication |
| Lithium |
Non-selective, direct |
Approved (bipolar disorder); tested in AD |
AD, [FTD[/diseases/[ftd[/diseases/[ftd[/diseases/[ftd[/diseases/[ftd--TEMP--/diseases)--FIX--, ALS |
| Tideglusib |
Non-ATP competitive (TDZD) |
Phase II completed (AD, PSP) |
AD, PSP, ALS, DM1 |
| AZD1080 |
ATP-competitive |
Phase I |
AD |
| LY2090314 |
ATP-competitive |
Phase I/II |
Cancer, neurodegeneration |
Lithium is the oldest and best-studied GSK-3β inhibitor (Ki ~2 mM), with direct inhibition by competition with magnesium and indirect inhibition through Akt activation. Epidemiological studies suggest chronic lithium use reduces dementia incidence. However, lithium lacks selectivity (also inhibits inositol monophosphatase) and has a narrow therapeutic window with significant side effects including nephrotoxicity and thyroid dysfunction [13].
Tideglusib is a thiadiazolidinone (TDZD) class non-ATP-competitive GSK-3β inhibitor that binds irreversibly to the enzyme. Despite [neuroprotection[/treatments/[neuroprotection[/treatments/[neuroprotection[/treatments/[neuroprotection[/treatments/[neuroprotection--TEMP--/treatments)--FIX-- in preclinical AD and PSP models, Phase II trials in AD (ARGO study) and PSP failed to meet primary cognitive endpoints. However, tideglusib showed biomarker improvements (reduced brain atrophy, CSF tau] changes) in subgroup analyses, and is being developed for [myotonic dystrophy[/diseases/[myotonic-dystrophy[/diseases/[myotonic-dystrophy[/diseases/[myotonic-dystrophy[/diseases/[myotonic-dystrophy--TEMP--/diseases)--FIX-- type 1 (DM1) [14].
- Broad substrate spectrum: GSK-3β has >100 substrates across metabolism, immune function, and development; systemic inhibition risks on-target toxicities
- Dose-limiting effects: Complete GSK-3β inhibition mimics Wnt pathway hyperactivation, raising concerns about β-catenin stabilization and tumorigenesis
- [BBB[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier--TEMP--/entities)--FIX-- penetration: CNS-directed therapy requires good brain exposure
- Isoform selectivity: Most inhibitors target both GSK-3α and GSK-3β; isoform-specific inhibition may improve safety
- Substrate-selective inhibition: Emerging strategies aim to selectively block GSK-3β-tau] interaction without affecting other substrates [15]
- Multi-target directed ligands (MTDLs): Bifunctional molecules targeting GSK-3β alongside cholinesterase, [BACE1[/entities/bace1://pubmed.ncbi.nlm.nih.gov/15890656/[/entities/bace1://pubmed.ncbi.nlm.nih.gov/15890656/[/entities/bace1://pubmed.ncbi.nlm.nih.gov/15890656/[/entities/bace1://pubmed.ncbi.nlm.nih.gov/15890656/--TEMP--/entities/bace1:/)--FIX--
- [Avila J, Lucas JJ, Perez M, Hernandez F. [Role of tau protein in both physiological and pathological conditions)(https://pubmed.ncbi.nlm.nih.gov/12445403/)
- [Bhat RV, Budd Haeberlein SL, Bhatt DK. [GSK3: A potential target and pending issues for treatment of Alzheimer's Disease)(https://pmc.ncbi.nlm.nih.gov/articles/PMC11215492/)
- [Frame S, Cohen P. [GSK3 takes centre stage more than 20 years after its discovery)(https://pubmed.ncbi.nlm.nih.gov/11461910/)
- Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 1995;378(6559]:785-789.
- [Jiang H, Guo W, Liang X, Rao Y. Both the establishment and the maintenance of neuronal polarity require active mechanisms)
- [Peineau S, Taghibiglou C, Bradley C, et al. [LTP inhibits LTD in the hippocampus via regulation of GSK3β)). [Neuron[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--. 2007;53(5):703-717.
- [Kolla R, et al. [GSK3β phosphorylation catalyzes the aggregation of tau into Alzheimer's Disease-like filaments)(https://pmc.ncbi.nlm.nih.gov/articles/PMC11671486/)
- [Sayas CL, Ávila J. [GSK-3 and Tau(/entities/tau-protein: A Key Duet in Alzheimer's Disease))(https://pmc.ncbi.nlm.nih.gov/articles/PMC8063930/). Cells. 2021;10(4):721.
- [Hooper C, Killick R, Lovestone S. [The GSK3 hypothesis of Alzheimer's Disease)(https://pubmed.ncbi.nlm.nih.gov/24231268/)
- [Jope RS, Yuskaitis CJ, Beurel E. [Glycogen synthase kinase-3 (GSK3: inflammation, diseases, and therapeutics))(https://pubmed.ncbi.nlm.nih.gov/21145935/)
- [Gao Y, et al. Therapeutic Potential Effect of Glycogen Synthase Kinase 3 Beta (GSK-3β Inhibitors in Parkinson Disease))
- [Eldar-Finkelman H, Martinez A. GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS—A Decade Onward)
- [Del Ser T, et al. Treatment of Alzheimer's Disease with the GSK-3 inhibitor tideglusib: a pilot study)
- [Pandey MK, DeGrado TR. Understanding Glycogen Synthase Kinase-3: A Novel Avenue for Alzheimer's Disease)
The study of Gsk 3Β has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- [/diseases/alzheimers[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--
- [/mechanisms/amyloid-hypothesis[/mechanisms/[amyloid-hypothesis[/mechanisms/[amyloid-hypothesis[/mechanisms/[amyloid-hypothesis[/mechanisms/[amyloid-hypothesis--TEMP--/mechanisms)--FIX--
- [/mechanisms/tau-pathology[/mechanisms/[tau-pathology[/mechanisms/[tau-pathology[/mechanisms/[tau-pathology[/mechanisms/[tau-pathology--TEMP--/mechanisms)--FIX--
- [/diseases/parkinsons[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--
- [/mechanisms/alpha-synuclein[/mechanisms/[alpha-synuclein[/mechanisms/[alpha-synuclein[/mechanisms/[alpha-synuclein[/mechanisms/[alpha-synuclein--TEMP--/mechanisms)--FIX--
- Frame S, Cohen P. GSK3 takes centre stage more than 20 years after its discovery. Biochem J. 2001;359(Pt 1]:1-16. DOI:10.1042/bj3590001
- Grimes CA, Jope RS. The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol. 2001;65(4]:391-426. [DOI:10.1016/s0301-0082(01](https://doi.org/10.1016/s0301-0082(01)]00011-9
- Jope RS, Johnson GV. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci. 2004;29(2]:95-102. DOI:10.1016/j.tibs.2003.12.004
- Beurel E, Grieco SF, Jope RS. Glycogen synthase kinase-3 (GSK3]: regulation, actions, and diseases. Pharmacol Ther. 2015;148:114-131. DOI:10.1016/j.pharmthera.2014.11.016
- Cohen P, Goedert M. GSK3 inhibitors: development and therapeutic potential. Nat Rev Drug Discov. 2004;3(6]:479-487. DOI:10.1038/nrd1415
- Martinez A, Castro A, Medina M. Glycogen synthase kinase 3 (GSK-3] and its inhibitors. Chichester: John Wiley & Sons; 2006.
- Licht-Murava A, Plotkin B, Eisenberg S, et al. Elucidating the structural basis of the interaction between GSK3beta and a peptide derived from GSK3beta. PLoS One. 2011;6(12]:e27359. DOI:10.1371/journal.pone.0027359
- Avila JA, Uvee A, Beldsoe G, et al. The Role of GSK-3 in Synaptic Plasticity. Front Mol Neurosci. 2022;15:861905. DOI:10.3389/fnmol.2022.861905## See Also
-
- [Neurodegenerative Diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/diseases
-
- [Genes Index[/[genes[/[genes[/[genes[/[genes[/[genes[/[genes[/[genes[/genes
-
- [Mechanisms of Neurodegeneration[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/mechanisms
-
- [Proteins Index[/[proteins[/[proteins[/[proteins[/[proteins[/[proteins[/[proteins[/[proteins[/proteins## External Links
-
-
-
- PubMed (function() { if (window.__nwRefTooltipBound) return; window.__nwRefTooltipBound = true; var tooltip = null; function ensureTooltip() { if (tooltip) return tooltip; tooltip = document.createElement('div'); tooltip.id = 'nw-ref-tooltip'; tooltip.style.position = 'fixed'; tooltip.style.zIndex = '9999'; tooltip.style.maxWidth = '420px'; tooltip.style.padding = '8px 10px'; tooltip.style.background = '#111'; tooltip.style.color = '#fff'; tooltip.style.borderRadius = '6px'; tooltip.style.fontSize = '12px'; tooltip.style.lineHeight = '1.4'; tooltip.style.display = 'none'; tooltip.style.pointerEvents = 'none'; tooltip.style.boxShadow = '0 6px 18px rgba(0,0,0,0.25)'; document.body.appendChild(tooltip); return tooltip; } document.addEventListener('mouseover', function(e) { var a = e.target.closest('a.ref-link'); if (!a) return; var text = a.getAttribute('data-ref-text') || a.getAttribute('title'); if (!text) return; var el = ensureTooltip(); el.textContent = text; el.style.display = 'block'; }); document.addEventListener('mousemove', function(e) { if (!tooltip || tooltip.style.display !== 'block') return; tooltip.style.left = (e.clientX + 12) + 'px'; tooltip.style.top = (e.clientY + 12) + 'px'; }); document.addEventListener('mouseout', function(e) { if (!tooltip) return; if (e.target.closest('a.ref-link')) { tooltip.style.display = 'none'; } }); })(); 16. (function() { if (window.__nwRefTooltipBound) return; window.__nwRefTooltipBound = true; var tooltip = null; function ensureTooltip() { if (tooltip) return tooltip; tooltip = document.createElement('div'); tooltip.id = 'nw-ref-tooltip'; tooltip.style.position = 'fixed'; tooltip.style.zIndex = '9999'; tooltip.style.maxWidth = '420px'; tooltip.style.padding = '8px 10px'; tooltip.style.background = '#111'; tooltip.style.color = '#fff'; tooltip.style.borderRadius = '6px'; tooltip.style.fontSize = '12px'; tooltip.style.lineHeight = '1.4'; tooltip.style.display = 'none'; tooltip.style.pointerEvents = 'none'; tooltip.style.boxShadow = '0 6px 18px rgba(0,0,0,0.25)'; document.body.appendChild(tooltip); return tooltip; } document.addEventListener('mouseover', function(e) { var a = e.target.closest('a.ref-link'); if (!a) return; var text = a.getAttribute('data-ref-text') || a.getAttribute('title'); if (!text) return; var el = ensureTooltip(); el.textContent = text; el.style.display = 'block'; }); document.addEventListener('mousemove', function(e) { if (!tooltip || tooltip.style.display !== 'block') return; tooltip.style.left = (e.clientX + 12) + 'px'; tooltip.style.top = (e.clientY + 12) + 'px'; }); document.addEventListener('mouseout', function(e) { if (!tooltip) return; if (e.target.closest('a.ref-link')) { tooltip.style.display = 'none'; } }); })();